NCT00005971 is a Phase 2 clinical trial of alvocidib in Melanoma (Skin), sponsored by NCIC Clinical Trials Group.

Who is sponsoring NCT00005971?

NCT00005971 is sponsored by NCIC Clinical Trials Group.

What drugs are being tested in NCT00005971?

Interventions in NCT00005971: alvocidib.

What condition does NCT00005971 study?

NCT00005971 studies Melanoma (Skin).

Is NCT00005971 still recruiting?

NCT00005971 is currently completed. Last updated 9 April 2020.

Last reviewed 2020-04-09 · How we verify

NCT00005971

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Completed Phase 2 Last updated 9 April 2020

What this trial tests

Phase 2 trial testing alvocidib in Melanoma (Skin) in 17 participants. Completed in 21 December 2009.

Timeline

4 July 2000

Primary endpoint
24 August 2001

21 December 2009

Quick facts

Lead sponsor	NCIC Clinical Trials Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	4 July 2000
Primary completion	24 August 2001
Estimated completion	21 December 2009
Sites	50 locations across Canada

Drugs / interventions tested

alvocidib — full drug profile →

Conditions studied

Melanoma (Skin) — all drugs for Melanoma (Skin) →

Sponsor

NCIC Clinical Trials Group

Who can join

Adults 18 to 120, any sex, with Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have metastatic malignant melanoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Current Molecular Markers of Melanoma and Treatment Targets.
Yang K, Oak ASW, Slominski RM, Brożyna AA, et al · · 2020 · cited 52× · PMID 32429485 · DOI 10.3390/ijms21103535
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z, Lim SY, Rizos H. · · 2020 · cited 28× · PMID 33076392 · DOI 10.3390/biom10101447
CDK4 inhibitors an emerging strategy for the treatment of melanoma.
Lee B, McArthur GA. · · 2015 · cited 16× · PMID 30190853 · DOI 10.2217/mmt.15.14
Biomarkers as key contributors in treating malignant melanoma metastases.
de Souza CF, Morais AS, Jasiulionis MG. · · 2012 · cited 14× · PMID 22110486 · DOI 10.1155/2012/156068
The Pharmacological Implications of Flavopiridol: An Updated Overview
Joshi H, Tuli H, Ranjan A, Chauhan A, et al · · 2023

Verify or expand the search:

Other trials of alvocidib

Trials testing the same drug.

NCT00005974 — Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma · Phase 2 · completed
NCT00005074 — Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma · Phase 2 · completed

Other recruiting trials for Melanoma (Skin)

Currently open trials in the same condition.

NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00005971 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
Last refreshed: 9 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00005971.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing